

Phone: 888-558-5227

651-644-8424

888-558-7329 Fax: Email: getinfo@lktlabs.com

lktlabs.com Web:

Product Information

Product ID C086007

CAS No. 1618658-88-0

Chemical Name

Synonym CC 671, CC671

Formula $C_{28}H_{28}N_6O_4$

Formula Wt. 512.57

Melting Point

Purity ≥98%

Solubility

Product ID Size C086007 1 mg C086007 5 mg C086007 25 mg

Store Temp -20°C Ship Temp Ambient

Description CC-671 is a dual TTK/CLK2 inhibitor. It acts by inhibiting the phosphorylation of KNL1 and SRp75, direct substrates of TTK and

CLK2. It is a monotherapy candidate for treatment of triple negative breast cancer.

References Riggs J., Nagy M., et al. The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen. J Med Chem. 60(21):8989-9002 (2017). PMID: 28991472.

> Zhu D., Xu S., et al. Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G1-S Checkpoint. Mol Cancer Ther. 17(8):1727-38 (2018). PMID: 29866747.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.